US STOCKS-Wall St jumps as Gilead data offsets virus fears; financials jump

Reuters

Warning: This material has been prepared by a third party company, Reuters, which is independent of Davy. Davy has not reviewed the material and accepts no responsibility for errors or omissions, or for the information or opinions contained therein. It does not constitute investment advice.

 (For a live blog on the U.S. stock market, click  LIVE/  or
type LIVE/ in a news window.)
    * Gilead analysis shows remdesivir reduced coronavirus death
risk
    * Carnival rises on plan to resume trips in phases
    * Indexes: Dow up 1.4%, S&P 500 up 1.1%, Nasdaq up 0.7%

 (Updates close with volume, other details)
    By Caroline Valetkevitch
    July 10 (Reuters) - U.S. stocks rose on Friday as a positive
analysis on Gilead Sciences Inc's antiviral drug to treat
COVID-19 helped to soothe investor worries over a record rise in
coronavirus cases in the United States, and as financial shares
surged.
    The Nasdaq posted its sixth record closing high in seven
days, but the index underperformed both the Dow and S&P 500, in
a reversal of the recent trend.
    The S&P 500 financials index  .SPSY  rose 3.5%, leading
sector gains and giving the S&P 500 its biggest boost. Bank of
America Corp  BAC.N  shares increased 5.5%, Citigroup Inc  C.N 
jumped 6.5% and JPMorgan Chase & Co  JPM.N  climbed 5.5% ahead
of their financial results next week, which will mark the onset
of the second-quarter earnings season.
    Rob Haworth, senior investment strategist at U.S. Bank
Wealth Management in Seattle, said there was a rotation "from
winners into laggards" in Friday's trading, with the earnings
period around the corner.
    The United States registered the largest single-day increase
in new COVID-19 infections globally for the second day in a row
on Thursday, forcing Americans to take new precautions. Several
states have already backpedaled on reopening plans.  urn:newsml:reuters.com:*:nL1N2EG13N
    Gilead's  GILD.O  remdesivir significantly improved clinical
recovery and reduced the risk of death in COVID-19 patients,
additional data from a late-stage study showed. The drugmaker's
shares climbed 2.2% as it said the finding required confirmation
in clinical trials.  urn:newsml:reuters.com:*:nL4N2EH2TR
    "That kind of dampened some of the concern that's been
building over the past few days around the increased virus cases
in the southern states," said Charlie Ripley, senior investment
strategist for Allianz Investment Management in Minneapolis.
    The Dow Jones Industrial Average  .DJI  rose 369.21 points,
or 1.44%, to 26,075.3, the S&P 500  .SPX  gained 32.99 points,
or 1.05%, to 3,185.04 and the Nasdaq Composite  .IXIC  added
69.69 points, or 0.66%, to 10,617.44.
    For the week, the Dow rose 1%, the S&P 500 gained 1.8% and
the Nasdaq jumped 4%.
    Overall profits for S&P 500 companies are expected to have
fallen more than 40% in the second quarter, which would be the
biggest quarterly decline since the financial crisis, according
to IBES data from Refinitiv.
     The first coronavirus cases in the United States were
identified in January and within weeks much of the economy was
shut down to slow the spread, throwing millions of Americans
into unemployment. Companies across a range of industries have
been dealing with the aftermath ever since.  urn:newsml:reuters.com:*:nL1N2EG1J9
     The S&P 500 is up more than 40% from its March bottom,
thanks in part to economic data that has pointed to a revival in
business activity in June.
    Carnival Corp  CCL.N  jumped 10.8% after the cruise line
operator said it was planning to resume operations in a phased
manner and would operate with a smaller fleet on its return.
 urn:newsml:reuters.com:*:nL4N2EH2XM
    Netflix Inc  NFLX.O  rose 8.1% after Goldman Sachs hiked its
price target on the video streaming service's shares.
    Advancing issues outnumbered declining ones on the NYSE by a
2.87-to-1 ratio; on Nasdaq, a 1.62-to-1 ratio favored advancers.
    The S&P 500 posted 19 new 52-week highs and no new lows; the
Nasdaq Composite recorded 85 new highs and 17 new lows.
    Volume on U.S. exchanges was 9.57 billion shares, compared
with the 11.93 billion average for the full session over the
last 20 trading days.    

 (Additional reporting by Medha Singh and C Nivedita in
Bengaluru; Editing by Marguerita Choy and Maju Samuel)
 ((caroline.valetkevitch@thomsonreuters.com; +1 646 223 6393;
Reuters Messaging:
caroline.valetkevitch.thomsonreuters.com@reuters.net))

Warning: This content may be provided by regulated and unregulated entities and is not created, reviewed or endorsed by Davy. It is provided for general information purposes only and does not constitute a recommendation or solicitation to purchase or sell any security or make any other type of investment or investment decision. Importantly, it does not constitute investment advice, as it does not contemplate the personal circumstances of any particular person or group of persons. Neither Davy nor the providers of the Third Party Content will be liable for any investment decision made based on the reliance on or use of such data, or any liability that may arise due to delays or interruptions in the delivery of the Third Party Content for any reason.